Articles

Author:  Dr. Carolyn Britton, President, National Medical Association

Measures of student achievement nationally suggest that states are not measuring up in terms of overall science and life science education.

BIOtech Now interviews Stephanie Adams, executive director of Southeast BIO. She discusses the growth of the biotechnology sector in the Southeast, the upcoming 2009 BIO International Convention in Atlanta, and the SE BIOtech Connect database of the more than 1,200 life sciences companies and research institutions in the Southeast. Download or listen to the program.

BIO has selected six companies as finalists in the "Be the Buzz of BIO" contest - see who made the list below! Now it's time to vote for your favorite - just go to http://community.convention.bio.org/Summit09/Contest-Vote/tabid/68/Defau... Voting is open until April 17. The finalist with the most votes will be chosen and notified on or about April 21st. Finalists: AMRI Archimedes Inc. Biobide S.L. Impact Systems Koronic Pharmaceuticals Zenda Technologies

Mexico is the fifth richest region in biodiversity in the world with a long tradition of research in biological sciences.

Executives of advanced biofuels, feedstock crop technology, and industrial biotechnology companies give an update on their progress in commercializing advanced biofuels. BIO presents principles for coordinating and enhancing existing federal policy supporting these companies’ efforts. Listen or download the program.

BIOtech Now's Tracy Krughoff speaks with Jonas Frisén of the Karolinska Institute in Stockholm, Sweden about his session on stem cells at the upcoming BIO International Convention. Listen or download the podcast.

BIOtech Now interviews Dr. Michael Rosenberg, President and CEO of Health Decisions. He discusses adaptive research methods which can streamline and improve the design of clinical trials and previews his upcoming presentation at the 2009 BIO International Convention. Listen or download the program.

CureDuchenne is a non-profit organization founded in 2003 by Debra and Paul Miller, parents of a Duchenne boy. CureDuchenne’s vision is its name to cure Duchenne muscular dystrophy. CureDuchenne aggressively seeks the most promising, leading edge research breakthroughs and expedites them to the clinical trial process. The ultimate goal…give the boys that have Duchenne now a chance to live a normal life by expediting the cure and/or the availability of therapies that can give quality of life to Duchenne boys, much like insulin does for diabetics.

Total job creation, accounting for economic multiplier effects, could reach 123,000 in 2012, 383,000 in 2016, and 807,000 by 2022.